Redeye is positive about Renaparin’s five-year follow-up data. While the dataset is small, the results are supportive of preclinical findings and the safety conclusions from RENAPAIR 01. Although Corline’s medtech business is currently the main focus, we argue that Renaparin remains worth monitoring, and we look forward to updates on the company’s partner search, which is crucial for progressing Renaparin into the Phase II trial.
LÄS MER
